

Applicants : Peter D. Kwong et al.
Serial No. : Not Yet Known
Filed : Herewith
Page 3

48.--

--57. (Amended) A composition comprising the compound of claim 55 and a suitable carrier.--

--90. (Amended) A vaccine comprising the variant of claim 86.

--94. (Amended) An antibody against the variant of claim 86.

Remarks:

Claims 1-96 are pending in the subject application. Applicants have herein canceled claims 2-20, 22-26, 29-32, 35, 39-41, 43, 50-52, 54, 60, 62-79, 82, 87-89, 92-93, 95-96 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a later-filed application and amended claims 33, 44, 46, 55, 57, 90 and 94. This amendment does not involve any issue of new matter. Therefore, entry of this amendment is respectfully requested such that claims 1, 21, 27-28, 33-34, 36-38, 42, 44-49, 53, 55-59, 61, 80-81, 83-86, 90-91 and 94 will be pending.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

No fee, other than the \$1,806.00 fee, which includes the \$710.00 basic national fee and the \$1,096.00 fee for additional claims is deemed necessary in connection with filing this Preliminary